Astellas Pharma has unveiled encouraging preliminary results from OPTION-VMS, its ongoing phase 4 observational study evaluating fezolinetant in women...
Lire la suiteENA Respiratory has closed a US$22.4 million (AU$34 million) Series B round to propel its lead therapy, INNA-051, into...
Lire la suiteMr Whippy is stepping beyond soft-serve and into the sweet-treat big league with a £15 million manufacturing site in...
Lire la suiteEnterome has secured Fast Track designation from the US Food and Drug Administration (FDA) for EO2463, its lead OncoMimics®...
Lire la suiteAdocia and Tonghua Dongbao have announced positive topline results from a Phase 3 clinical trial of BioChaperone® Lispro (THDB0206...
Lire la suiteLancashire-based confectioner Stockley’s has completed a major expansion, moving into a new 60,000 sq ft facility in Burnley as...
Lire la suite